Overexpression of hepatocyte nuclear factor-3α induces apoptosis through the upregulation and accumulation of cytoplasmic p53 in prostate cancer cells

Prostate

Volumn 70, Issue 4, 2010, Pages 353-361

  Lee, Hyun Joo ^a   Chattopadhyay, Soma ^a   Yoon, Wan Hee ^b   Bahk, Jong Yoon ^c   Kim, Tae Hyoung ^d   Kang, Hyung Sik ^a   Lee, Keesook ^a  

^a Chonnam National University   (South Korea)

^b Chungnam National University   (South Korea)

^c Gyeongsang National University   (South Korea)

^d Chosun University College of Medicine   (South Korea)

Author keywords

Apoptosis; HNF 3 ; p53; Prostate cancer

Indexed keywords

ADENOVIRUS VECTOR; CASPASE; CASPASE 8; CYTOCHROME C; DEATH RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; PROTEIN BAX; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME RELEASE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; NICK END LABELING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS RECOMBINANT;

ADENOVIRIDAE; APOPTOSIS; CASPASES; CELL FRACTIONATION; CELL LINE, TUMOR; CYTOPLASM; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; IN SITU NICK-END LABELING; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 76149127352     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21069     Document Type: Article

References (45)

1. Isaacs JT. Role of androgens in prostatic cancer. Vitam Horm 1994;49:433-502.
2. Kopachik W, Hayward SW, Cunha GR. Expression of hepatocyte nuclear factor-3alpha in rat prostate, seminal vesicle, and bladder. Dev Dynam 1998;211:131-140.
3. Peterson RS, Clevidence DE, Ye H, Costa RH. Hepatocyte nuclear factor-3 alpha promoter regulation involves recognition by cell-specific factors, thyroid transcription factor-1, and autoactivation. Cell Growth Differ 1997;8:69-82.
4. Habashy HO, Powe DG, Rakha EA, Ball G, Paish C, Gee J, Nicholson RI, Ellis IO. Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer 2008; 44:1541-1551.
5. Gipp J, Gu G, Crylen C, Susan K, Bushman W. Hedgehog pathway activity in the LADY prostate tumor model. Mol Cancer 2007;7:1-8.
6. Gao N, Ishii K, Mirosevich J, Kuwajima S, Oppenheimer SR, Robert RL, Jiang M, Yu X, Shappell SB, Caprioli RM, Stoffel M, Hayward SW, Matusik RJ. Fokhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development 2005;132:3431-3443.
7. Yu X, Gupta A, Wang Y, Suzuki K, Mirosevich J, Orgebin-Crist M, Matusik R. Foxa1 and Foxa2 interact with the androgen receptor to regulate prostate and epididymal genes differentially. Ann NY Acad Sci 2005;161:77-93.
8. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV, Sawyers CL. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003;4:223-238.
9. Gao N, Zhang J, Rao MA, Case TC, Mirosevich J, Wang Y, Jin R, Gupta A, Rennie PS, Matusik RJ. The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol Endocrinol 2003;17:1484-1507.
10. Lee HJ, Hwang MO, Chattopadhyay S, Choi H, Lee K. Hepatocyte nuclear factor-3 alpha (HNF-3a) negatively regulates androgen receptor transactivation in prostate cancer cells. Biochem Biophys Res Commun 2008;367:481-486.
11. Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ III, Emanuel BS, Rovera G, Barr FG. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993;5:230-235.
12. Weigel D, Jurgens G, Kuttner F, Seifert E, Jackle H. The homeotic gene fork head encodes a nuclear protein and is expressed in the terminal regions of the Drosophila embryo. Cell 1989;57:645-658.
13. Xu L, Hui L, Wang S, Gong J, Jin Y, Wang Y, Ji Y, Wu X, Han Z, Hu G. Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res 2001;61:3176-3181.
14. Halmos B, Basseres DS, Monti S, D'Alo F, Dayaram T, Ferenczi K, Wouters BJ, Huettner CS, Golub TR, Tenen DG. A transcriptional profiling study of CCAAT/enhancer binding protein targets identifies hepatocyte nuclear factor 3 beta as a novel tumor suppressor in lung cancer. Cancer Res 2004;64:4137-4147.
15. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282:1497-1501.
16. Kim H, Kwak N, Lee JY, Choi BH, Lim Y, Ko YJ, Kim Y, Huh P, Lee K, Rha HK, Wang Y. Merlin neutralizes the inhibitory effect of Mdm2 on p53. J Biol Chem 2004;279:7812-7818.
17. Ohtsuka T, Ryu H, Minamishima YA, Macip S, Sagara J, Nakayama K, Aaronson SA, Lee SW. ASC is a Bax adaptor and regulates the p53-Bax mitochondrial apoptosis pathway. Nature 2004;6:121-128.
18. Chattopadhyay S, Gong EY, Hwang M, Park E, Lee HJ, Hong CY, Choi HS, Cheong JH, Kwon HB, Lee K. The CCAAT enhancer-binding protein-alpha negatively regulates the transactivation of androgen receptor in prostate cancer cells. Mol Endocrinol 2006;20:984-995.
19. Kim TW, Kwon YJ, Kim JM, Song YH, Kim SN, Kim YJ. MED16 and MED23 of mediator are coactivators of lipopolysaccharide-and heat-shock-induced transcriptional activators. Proc Natl Acad Sci USA 2004;101:12153-12158.
20. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000;102:33-42.
21. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-489.
22. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c. Cell 1996;86:147-157.
23. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000;102:43-53.
24. Ko LJ, Prives C. p53: Puzzle and paradigm. Genes Dev 1996; 10:1054-1072.
25. Yoshida Y, Izumi H, Torigoe T, Ishiguchi H, Itoh H, Kang D, Kohno K. p53 physically interacts with mitochondrial transcription factor A and differentially regulates binding to damaged DNA. Cancer Res 2003;63:3729-3734.
26. Rocha S, Martin AM, Meek DW, Perkins ND. p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association the p52NF-κB subunit with histone deacetylase 1. Mol Cell Biol 2003;23:4713-4727.
27. Burlacu A. Regulation of apoptosis by Bcl-2 family proteins. J Cell Mol Med 2003;7:249-257.
28. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003;11:577-590.
29. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004;303:1010-1014.
30. Tomita Y, Marchenko N, Erster S, Nemajerova A, Dehner A, Klein C, Pan H, Kessler H, Pancoska P, Moll UM. p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem 2006;281:8600-8606.
31. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281:1309-1312.
32. Yin Y, Stephen CW, Luciani MG, Fahraeus R. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol 2002;4:462-467.
33. van Bokhoven A, Vallera-Garcia M, Korch C, Hessels D, Miller GJ. Widely used prostate carcinoma cell lines share common origins. Prostate 2001;47:36-51.
34. Ashcroft M, Vousden KH. Regulation of p53 stability. Oncogene 1999;18:7637-7643.
35. Vousden KH. Activation of the p53 tumor suppressor protein. Biochem Biophys Acta 2002;1606:47-59.
36. Bae MK, Ahn MY, Jeong JW, Bae MH, Lee YM, Bae SK, Park JW, Kim KR, Kim KW. ab1 interacts directly with HIF-1alpha and regulates its stability. J Biol Chem 2002;277:9-12.
37. Giandomenico V, Simonsson M, Gronroos E, Ericsson J. Coactivator- dependent acetylation stabilizes members of the SREBP family of transcription factors. Mol Cell Biol 2003;23: 2587-2599.
38. Kong HJ, Park MJ, Hong S, Yu HJ, Lee YC, Choi YH, Cheong J. Hepatitis B virus X protein regulates transactivation activity and protein stability of the cancer-amplified transcription coactivator ASC-2. Hepatology 2003;38:1258-1266.
39. Haupt Y, Maya R, Kazaz A, Oren M. MDM2 promotes the rapid degradation of p53. Nature 1997;387:296-299.
40. Shirangi TR, Zaika A, Moll UM. Nuclear degradation of p53 occurs during down-regulation of the p53 response after DNA damage. FASEB J 2002;16:420-422.
41. Li H, Kolluri SK, Gu J, Dawson MI, Cao X, Hobbs PD, Lin B, Chen G, Lu J, Lin F, Xie Z, Fontana JA, Reed JC, Zhang X. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 2000;289:1159-1164.
42. Lin B, Kolluri SK, Lin F, Liu W, Han YH, Cao X, Dawson MI, Reed JC, Zhang XK. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004; 116:527-540.
43. Bonini P, Cicconi S, Cardinale A, Vitale C, Serafino AL, Ciotti MT, Marlier LN. Oxidative stress induces p53-mediated apoptosis in glia: p53 transcription-independent way to die. J Neurosci Res 2004;75:83-95.
44. Marchenko ND, Zaika A, Moll UM. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem 2000;275:16202-16212.
45. Yee KS, Vousden KH. Complicating the complexity of p53. Carcinogenesis 2005;26:1317-1322.